Dose Regimen Rationale for Panitumumab in Cancer Patients: To Be Based on Body Weight or Not.
Michael Z LiaoMarloes BerkhoutHans PrenenSandeep DuttaVijay V UpretiPublished in: Clinical pharmacology : advances and applications (2020)
Results demonstrate that the weight-based dose (6 mg/kg) reduced variability in panitumumab exposure across the range of body weights compared with the fixed-dose approach, indicating that a body weight-based approach is the recommended patient dosing strategy.